[{"drugId":"CHEMBL3039540","drugName":"ADUCANUMAB","type":"Antibody","mechanismOfAction":"Beta amyloid A4 protein binding agent","actionType":["Binding agent"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":4,"status":null,"source":["https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761178s000lbl.pdf"]},{"drugId":"CHEMBL3833321","drugName":"LECANEMAB","type":"Antibody","mechanismOfAction":"Beta amyloid A4 protein inhibitor","actionType":["Binding agent"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":4,"status":null,"source":["https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761269Orig1s000lbl.pdf"]},{"drugId":"CHEMBL149082","drugName":"TRAMIPROSATE","type":"Small molecule","mechanismOfAction":"Beta amyloid A4 protein stabiliser","actionType":["Binding agent"],"diseaseId":"HP_0100543","diseaseName":"Cognitive impairment","phase":4,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05022186"]},{"drugId":"CHEMBL3039540","drugName":"ADUCANUMAB","type":"Antibody","mechanismOfAction":"Beta amyloid A4 protein binding agent","actionType":["Binding agent"],"diseaseId":"HP_0000726","diseaseName":"Dementia","phase":4,"status":null,"source":["https://www.whocc.no/atc_ddd_index/?code=N06DX03"]},{"drugId":"CHEMBL149082","drugName":"TRAMIPROSATE","type":"Small molecule","mechanismOfAction":"Beta amyloid A4 protein stabiliser","actionType":["Binding agent"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":3,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT00314912"]},{"drugId":"CHEMBL1743025","drugName":"GANTENERUMAB","type":"Antibody","mechanismOfAction":"Beta amyloid A4 protein binding agent","actionType":["Binding agent"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":3,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT03443973","https://clinicaltrials.gov/study/NCT04339413","https://clinicaltrials.gov/study/NCT05256134","https://clinicaltrials.gov/study/NCT04374253","https://clinicaltrials.gov/study/NCT03444870"]},{"drugId":"CHEMBL4297245","drugName":"DONANEMAB","type":"Antibody","mechanismOfAction":"Beta amyloid A4 protein disrupting agent","actionType":["Binding agent"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":3,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT05026866"]},{"drugId":"CHEMBL1743004","drugName":"CRENEZUMAB","type":"Antibody","mechanismOfAction":"Beta amyloid A4 protein inhibitor","actionType":["Binding agent"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":3,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT03114657","https://clinicaltrials.gov/study/NCT02670083","https://clinicaltrials.gov/study/NCT03491150"]},{"drugId":"CHEMBL3833321","drugName":"LECANEMAB","type":"Antibody","mechanismOfAction":"Beta amyloid A4 protein inhibitor","actionType":["Binding agent"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":3,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT03887455"]},{"drugId":"CHEMBL4650301","drugName":"VALILTRAMIPROSATE","type":"Small molecule","mechanismOfAction":"Beta amyloid A4 protein stabiliser","actionType":["Binding agent"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":3,"status":"Not yet recruiting","source":["https://clinicaltrials.gov/study/NCT06304883"]},{"drugId":"CHEMBL2108576","drugName":"BAPINEUZUMAB","type":"Antibody","mechanismOfAction":"Beta amyloid A4 protein binding agent","actionType":["Binding agent"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":3,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00676143","https://clinicaltrials.gov/study/NCT00996918","https://clinicaltrials.gov/study/NCT00998764","https://clinicaltrials.gov/study/NCT00667810","https://clinicaltrials.gov/study/NCT00937352"]},{"drugId":"CHEMBL3039540","drugName":"ADUCANUMAB","type":"Antibody","mechanismOfAction":"Beta amyloid A4 protein binding agent","actionType":["Binding agent"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":3,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT02484547","https://clinicaltrials.gov/study/NCT02477800"]},{"drugId":"CHEMBL4297245","drugName":"DONANEMAB","type":"Antibody","mechanismOfAction":"Beta amyloid A4 protein disrupting agent","actionType":["Binding agent"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":3,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT04437511"]},{"drugId":"CHEMBL1743072","drugName":"SOLANEZUMAB","type":"Antibody","mechanismOfAction":"Beta amyloid A4 protein binding agent","actionType":["Binding agent"],"diseaseId":"HP_0100543","diseaseName":"Cognitive impairment","phase":3,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02008357"]},{"drugId":"CHEMBL1743025","drugName":"GANTENERUMAB","type":"Antibody","mechanismOfAction":"Beta amyloid A4 protein binding agent","actionType":["Binding agent"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":3,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01224106","https://clinicaltrials.gov/study/NCT02051608"]},{"drugId":"CHEMBL1743072","drugName":"SOLANEZUMAB","type":"Antibody","mechanismOfAction":"Beta amyloid A4 protein binding agent","actionType":["Binding agent"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":3,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00904683","https://clinicaltrials.gov/study/NCT00905372"]},{"drugId":"CHEMBL3833321","drugName":"LECANEMAB","type":"Antibody","mechanismOfAction":"Beta amyloid A4 protein inhibitor","actionType":["Binding agent"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":3,"status":"Recruiting","source":["https://clinicaltrials.gov/study/NCT04468659"]},{"drugId":"CHEMBL2108576","drugName":"BAPINEUZUMAB","type":"Antibody","mechanismOfAction":"Beta amyloid A4 protein binding agent","actionType":["Binding agent"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":3,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00574132","https://clinicaltrials.gov/study/NCT00575055"]},{"drugId":"CHEMBL4650301","drugName":"VALILTRAMIPROSATE","type":"Small molecule","mechanismOfAction":"Beta amyloid A4 protein stabiliser","actionType":["Binding agent"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":3,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT04770220"]},{"drugId":"CHEMBL1743072","drugName":"SOLANEZUMAB","type":"Antibody","mechanismOfAction":"Beta amyloid A4 protein binding agent","actionType":["Binding agent"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":3,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT01900665","https://clinicaltrials.gov/study/NCT01127633","https://clinicaltrials.gov/study/NCT02760602"]},{"drugId":"CHEMBL3039540","drugName":"ADUCANUMAB","type":"Antibody","mechanismOfAction":"Beta amyloid A4 protein binding agent","actionType":["Binding agent"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":3,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT04241068","https://clinicaltrials.gov/study/NCT05310071"]},{"drugId":"CHEMBL2108576","drugName":"BAPINEUZUMAB","type":"Antibody","mechanismOfAction":"Beta amyloid A4 protein binding agent","actionType":["Binding agent"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00606476","https://clinicaltrials.gov/study/NCT00916617"]},{"drugId":"CHEMBL2108328","drugName":"AMILOMOTIDE","type":"Protein","mechanismOfAction":"Beta amyloid A4 protein vaccine antigen","actionType":["Binding agent"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00795418","https://clinicaltrials.gov/study/NCT00956410","https://clinicaltrials.gov/study/NCT01023685","https://clinicaltrials.gov/study/NCT01097096","https://clinicaltrials.gov/study/NCT00733863"]},{"drugId":"CHEMBL1743058","drugName":"PONEZUMAB","type":"Antibody","mechanismOfAction":"Beta amyloid A4 protein binding agent","actionType":["Binding agent"],"diseaseId":"EFO_0006790","diseaseName":"cerebral amyloid angiopathy","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01821118"]},{"drugId":"CHEMBL2108576","drugName":"BAPINEUZUMAB","type":"Antibody","mechanismOfAction":"Beta amyloid A4 protein binding agent","actionType":["Binding agent"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01254773","https://clinicaltrials.gov/study/NCT00663026","https://clinicaltrials.gov/study/NCT00112073"]},{"drugId":"CHEMBL2108058","drugName":"VANUTIDE CRIDIFICAR","type":"Protein","mechanismOfAction":"Beta amyloid A4 protein vaccine antigen","actionType":["Binding agent"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT00960531","https://clinicaltrials.gov/study/NCT01238991"]},{"drugId":"CHEMBL2108328","drugName":"AMILOMOTIDE","type":"Protein","mechanismOfAction":"Beta amyloid A4 protein vaccine antigen","actionType":["Binding agent"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT02565511"]},{"drugId":"CHEMBL1743058","drugName":"PONEZUMAB","type":"Antibody","mechanismOfAction":"Beta amyloid A4 protein binding agent","actionType":["Binding agent"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00945672","https://clinicaltrials.gov/study/NCT00722046"]},{"drugId":"CHEMBL2109300","drugName":"GSK933776","type":"Antibody","mechanismOfAction":"Beta amyloid A4 protein binding agent","actionType":["Binding agent"],"diseaseId":"EFO_1001492","diseaseName":"atrophic macular degeneration","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01342926"]},{"drugId":"CHEMBL4650301","drugName":"VALILTRAMIPROSATE","type":"Small molecule","mechanismOfAction":"Beta amyloid A4 protein stabiliser","actionType":["Binding agent"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT04693520"]},{"drugId":"CHEMBL2108058","drugName":"VANUTIDE CRIDIFICAR","type":"Protein","mechanismOfAction":"Beta amyloid A4 protein vaccine antigen","actionType":["Binding agent"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00479557","https://clinicaltrials.gov/study/NCT01284387","https://clinicaltrials.gov/study/NCT00959192","https://clinicaltrials.gov/study/NCT01227564","https://clinicaltrials.gov/study/NCT00752232","https://clinicaltrials.gov/study/NCT00498602"]},{"drugId":"CHEMBL4297245","drugName":"DONANEMAB","type":"Antibody","mechanismOfAction":"Beta amyloid A4 protein disrupting agent","actionType":["Binding agent"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT03367403"]},{"drugId":"CHEMBL149082","drugName":"TRAMIPROSATE","type":"Small molecule","mechanismOfAction":"Beta amyloid A4 protein stabiliser","actionType":["Binding agent"],"diseaseId":"EFO_0000712","diseaseName":"stroke","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00056238"]},{"drugId":"CHEMBL1743025","drugName":"GANTENERUMAB","type":"Antibody","mechanismOfAction":"Beta amyloid A4 protein binding agent","actionType":["Binding agent"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":2,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT04592341"]},{"drugId":"CHEMBL1743004","drugName":"CRENEZUMAB","type":"Antibody","mechanismOfAction":"Beta amyloid A4 protein inhibitor","actionType":["Binding agent"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01998841","https://clinicaltrials.gov/study/NCT01397578","https://clinicaltrials.gov/study/NCT03977584","https://clinicaltrials.gov/study/NCT01723826","https://clinicaltrials.gov/study/NCT01343966"]},{"drugId":"CHEMBL1743072","drugName":"SOLANEZUMAB","type":"Antibody","mechanismOfAction":"Beta amyloid A4 protein binding agent","actionType":["Binding agent"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":2,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00329082","https://clinicaltrials.gov/study/NCT01148498","https://clinicaltrials.gov/study/NCT00749216"]},{"drugId":"CHEMBL2108576","drugName":"BAPINEUZUMAB","type":"Antibody","mechanismOfAction":"Beta amyloid A4 protein binding agent","actionType":["Binding agent"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":2,"status":"Unknown status","source":["https://clinicaltrials.gov/study/NCT00174525"]},{"drugId":"CHEMBL3833321","drugName":"LECANEMAB","type":"Antibody","mechanismOfAction":"Beta amyloid A4 protein inhibitor","actionType":["Binding agent"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":2,"status":"Active, not recruiting","source":["https://clinicaltrials.gov/study/NCT01767311"]},{"drugId":"CHEMBL2109300","drugName":"GSK933776","type":"Antibody","mechanismOfAction":"Beta amyloid A4 protein binding agent","actionType":["Binding agent"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00459550","https://clinicaltrials.gov/study/NCT01424436"]},{"drugId":"CHEMBL3833321","drugName":"LECANEMAB","type":"Antibody","mechanismOfAction":"Beta amyloid A4 protein inhibitor","actionType":["Binding agent"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02094729"]},{"drugId":"CHEMBL3039540","drugName":"ADUCANUMAB","type":"Antibody","mechanismOfAction":"Beta amyloid A4 protein binding agent","actionType":["Binding agent"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02434718","https://clinicaltrials.gov/study/NCT02782975","https://clinicaltrials.gov/study/NCT01397539"]},{"drugId":"CHEMBL2109300","drugName":"GSK933776","type":"Antibody","mechanismOfAction":"Beta amyloid A4 protein binding agent","actionType":["Binding agent"],"diseaseId":"EFO_1001492","diseaseName":"atrophic macular degeneration","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02033668"]},{"drugId":"CHEMBL2108328","drugName":"AMILOMOTIDE","type":"Protein","mechanismOfAction":"Beta amyloid A4 protein vaccine antigen","actionType":["Binding agent"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00411580"]},{"drugId":"CHEMBL4650301","drugName":"VALILTRAMIPROSATE","type":"Small molecule","mechanismOfAction":"Beta amyloid A4 protein stabiliser","actionType":["Binding agent"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT04157712","https://clinicaltrials.gov/study/NCT04585347"]},{"drugId":"CHEMBL3039540","drugName":"ADUCANUMAB","type":"Antibody","mechanismOfAction":"Beta amyloid A4 protein binding agent","actionType":["Binding agent"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":1,"status":"Terminated","source":["https://clinicaltrials.gov/study/NCT01677572"]},{"drugId":"CHEMBL2108576","drugName":"BAPINEUZUMAB","type":"Antibody","mechanismOfAction":"Beta amyloid A4 protein binding agent","actionType":["Binding agent"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00397891"]},{"drugId":"CHEMBL1743025","drugName":"GANTENERUMAB","type":"Antibody","mechanismOfAction":"Beta amyloid A4 protein binding agent","actionType":["Binding agent"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT00531804","https://clinicaltrials.gov/study/NCT01656525"]},{"drugId":"CHEMBL4297245","drugName":"DONANEMAB","type":"Antibody","mechanismOfAction":"Beta amyloid A4 protein disrupting agent","actionType":["Binding agent"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02624778","https://clinicaltrials.gov/study/NCT01837641"]},{"drugId":"CHEMBL1743004","drugName":"CRENEZUMAB","type":"Antibody","mechanismOfAction":"Beta amyloid A4 protein inhibitor","actionType":["Binding agent"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT02353598"]},{"drugId":"CHEMBL1743058","drugName":"PONEZUMAB","type":"Antibody","mechanismOfAction":"Beta amyloid A4 protein binding agent","actionType":["Binding agent"],"diseaseId":"MONDO_0004975","diseaseName":"Alzheimer disease","phase":1,"status":"Completed","source":["https://clinicaltrials.gov/study/NCT01005862","https://clinicaltrials.gov/study/NCT00455000","https://clinicaltrials.gov/study/NCT00733642","https://clinicaltrials.gov/study/NCT01125631","https://clinicaltrials.gov/study/NCT00607308"]}]